Clinical trials: Asthma Patients
Allergy
Tolerability of ALK Tree Tablet
This trial is performed to assess the tolerability of the ALK Tree Tablet in patients with birch pollen induced allergy
- Trial name
- NCT00535639
- Testing
- Betula Verrucosa allergen extract
- Where
- Denmark
- Sponsor
- ALK-Abelló A/S
Bronchial Asthma
Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-
This study evaluates the long-term (24-week) safety and efficacy of GW815SF Salmeterol/fluticasone propionate(HFA MDI) 50/100mcg(administered as 2 inhalations of 25/50mcg) bid in pediatric patients with bronchial asthma.
- Trial name
- NCT00449046
- Testing
- GW815SF Salmeterol/Fluticasone propionate(HFA MDI)
- Where
- 3 sites in Japan
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Allergic Rhinitis, Rhinoconjunctivitis
Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice
This is an observational prospective study to assess the tolerability and safety of treatment of SCIT Allergovac Poliplus polymerized in depot presentation.
- Conditions
- Allergic Rhinitis, Rhinoconjunctivitis, Asthma
- Trial name
- APOLO (NCT02844842)
- Testing
- Allergovac Poliplus
- Where
- 15 sites in Spain
- Volunteers
- 152 people
- Sponsor
- Roxall Medicina España S.A
Asthma
A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy of lebrikizumab compared with placebo, as measured by the ability of participants to achieve lower daily doses of…
- Trial name
- NCT01987492
- Testing
- Lebrikizumab
- Where
- 71 sites in United States, Australia and 14 more
- Volunteers
- 230 people
- Sponsor
- Hoffmann-La Roche
Allergy, Rhinitis
Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation
Efficacy and Safety from a high-dosed sublingual grass pollen preparation
- Conditions
- Allergy, Rhinitis, Conjunctivitis
- Trial name
- ALLEGRA6 (NCT00623701)
- Testing
- Allerslit forte
- Where
- Germany
- Volunteers
- 126 people
- Sponsor
- Allergopharma GmbH & Co. KG
Asthma
Study Phase III Study to Assess the Efficacy and Safety of SOTB07 in Asthma Patients
The objective of this study is to assess the efficacy and safety of SOTB07 in asthma patients by observing changes FEV1 (% predicted) as the primary efficacy endpoint after oral administration of SOTB07 200mg, 400mg, placebo for…
- Trial name
- NCT01907763
- Testing
- SOTB07 200mg, SOTB07 400mg
- Where
- South Korea
- Volunteers
- 194 people
- Sponsor
- SK Chemicals Co., Ltd.
Asthma
A Placebo and Active Controlled Study of ONO-6950 Following Allergen Challenge in Patients With Asthma
The primary objectives are to determine the effect of ONO-6950 200 mg QD versus placebo administered for 8 days on early asthmatic response (EAR) and late asthmatic response (LAR) induced by inhaled allergen to determine the…
- Trial name
- NCT01551147
- Testing
- ONO-6950, Montelukast
- Where
- 5 sites in Canada
- Volunteers
- 25 people
- Sponsor
- Ono Pharma USA Inc
Asthma
Effect of RNS60 on the Late Phase Asthmatic Response to Allergen Challenge
The study will investigate the effect of treatment with RNS60 for 21 days. Subjects' FEV1 will be measured after an inhaled allergen challenge at baseline and again after 21 days of treatment.
- Trial name
- NCT02422121
- Testing
- RNS60
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Revalesio Corporation
Mild Atopic Asthma
A Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers and Participants With Mild Atopic Asthma
This randomized, observer-blinded, placebo-controlled, single and multiple ascending-dose study will be conducted in two parts to evaluate the safety, pharmacokinetics, and immunogenicity of BITS7201A.
- Trial name
- NCT02748642
- Testing
- BITS7201A
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Asthma, Chronic Obstructive Pulmonary Disease
Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of ARO-MUC5AC in normal healthy volunteers (NHVs), patients with moderate-to-severe asthma and patients with moderate-to-severe chronic…
- Trial name
- NCT05292950
- Testing
- ARO-MUC5AC
- Where
- 13 sites in Australia, New Zealand and 5 more
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Mild Asthma
Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma
The objective of this study is to evaluate the pharmacodynamic (PD) bioequivalence (BE) of albuterol inhalers, test formulation: Albuterol Sulfate HFA inhalation aerosol 108 mcg (equal to albuterol base 90 mcg) per actuation and…
- Trial name
- NCT04912596
- Testing
- Albuterol Sulfate inhalation aerosol 108 mcg per actuation, Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation, Methacholine
- Where
- 12 sites in India, Taiwan
- Volunteers
- 148 people
- Sponsor
- Intech Biopharm Ltd.
Asthma
Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients
The primary objective of the study is to show similarity of efficacy on Pulmicort Respules 1.0 mg/day or 2.0 mg/day for 6 weeks in the treatment period and the corresponding doses of Pulmicort Turbuhaler 400 μg/day or 800 μg/day…
- Trial name
- NCT00855959
- Testing
- Budesonide, Pulmicort Turbuhaler
- Where
- 6 sites in Japan
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.
GSK961081 is a potent dual pharmacophore that demonstrates both antimuscarinic and beta-agonist pharmacology in preclinical studies, both pharmacologies being of long duration.
- Trial name
- NCT00674817
- Testing
- 400 microgrammes GSK961081, 1200 microgrammes GSK961081
- Where
- 4 sites in New Zealand, Thailand and 1 more
- Volunteers
- 45 people
- Sponsor
- Theravance Biopharma
Asthma
TELICAST : Telithromycin in Acute Exacerbations of Asthma
Primary Objective: The primary objective is to evaluate the clinical efficacy of telithromycin versus placebo as a supplement to the usual standard of care during an acute exacerbation of asthma.
- Trial name
- NCT00273520
- Testing
- Telithromycin
- Sponsor
- Sanofi
Asthma
Impact of Tiotropium Add-on Therapy in Patients With Asthma
To evaluate the effectiveness of add on therapy with Tiotropium Respimat® compared to increasing the dose of ICS in patients with a diagnosis of Asthma and on ICS/LABA therapy
- Trial name
- NCT03964220
- Testing
- Tiotropium Respimat®, Inhaled Corticosteroid/Long-acting beta-agonist
- Where
- United States
- Volunteers
- 7,857 people
- Sponsor
- Boehringer Ingelheim
Asthma
Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma
This study planned to assess the effect on the reduction in rate of severe asthma exacerbations of different dose levels of QGE031 in asthma patients that are inadequately controlled with inhaled steroid plus beta-2 agonist…
- Trial name
- NCT02336425
- Testing
- QGE031
- Where
- 37 sites in United States, Belgium and 8 more
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations
The aim is to study whether the budesonide component within the budesonide/ formoterol combination inhaler has additive value in a model of "slow onset acute asthma" , namely three AMP provocation tests performed on one day
- Trial name
- NCT00272753
- Testing
- budesonide/formoterol Turbuhaler, formoterol Turbuhaler, salbutamol
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Allergic Asthma
Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children
The purpose of this extension study is to assess the long-term safety and tolerability of omalizumab as an add-on therapy in Japanese pediatric patients (6 to 15 years of age) with inadequately controlled allergic asthma despite…
- Trial name
- NCT01328886
- Testing
- Omalizumab
- Where
- 15 sites in Japan
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Allergic Asthma
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
The purpose of this study is to assess the therapeutic potential and safety/tolerability of study drug (CYT003) at 3 dose levels versus placebo in patients with persistent moderate to severe allergic asthma not sufficiently…
- Trial name
- NCT01673672
- Testing
- CYT003
- Where
- 34 sites in United States, Czechia and 6 more
- Volunteers
- 365 people
- Sponsor
- Cytos Biotechnology AG
Asthma
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
Study CQMF149A2210 evaluated the safety of QMF149 Twisthaler® 500/400 μg, a fixed dose combination of indacaterol 500 μg, a once daily β2 agonist, and mometasone furoate 400 μg, an inhaled corticosteroid (ICS) that is approved…
- Trial name
- NCT00941798
- Testing
- QMF149 Twisthaler®, Mometasone Twisthaler®
- Where
- 146 sites in United States, Brazil and 7 more
- Volunteers
- 2,283 people
- Sponsor
- Novartis Pharmaceuticals